Bad Blood by John Carreyrou
Secrets and Lies in a Silicon Valley Startup

No critic rating

Waiting for minimum critic reviews

See 1 Critic Review

The question of how it got so far — more than 800 employees and a paper valuation of $9 billion — will fascinate business school classes for years. The first line of defense should have been the board, and its failure was shocking.
-NY Times

Synopsis

A National Besteller

"Chilling…Reads like a West Coast version of All the President’s Men." —The New York Times Book Review

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.

A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
 
 

About John Carreyrou

See more books from this Author
 
Published May 21, 2018 by Knopf. 320 pages
Genres: Political & Social Sciences, History, Nature & Wildlife, Science & Math, Biographies & Memoirs, Education & Reference. Non-fiction
Bestseller Status:
icon10
Rank this week
icon6
Peak Rank on Jul 08 2018
icon6
Weeks as Bestseller
Add Critic Review

Critic reviews for Bad Blood
All: 1 | Positive: 1 | Negative: 0

NY Times

Above average
Reviewed by Roger Lowenstein on May 21 2018

The question of how it got so far — more than 800 employees and a paper valuation of $9 billion — will fascinate business school classes for years. The first line of defense should have been the board, and its failure was shocking.

Read Full Review of Bad Blood: Secrets and Lies i... | See more reviews from NY Times

Reader Rating for Bad Blood
98%

An aggregated and normalized score based on 297 user ratings from iDreamBooks & iTunes


Rate this book!

Add Review
×